MetaVia Stock Moves Ahead of the Open After Obesity-Drug Data Picked for ADA
MetaVia Inc. jumped in U.S. pre-market trade Tuesday after saying three late-breaking abstracts for its cardiometabolic drug programs got into the American Diabetes Association’s 2026 Scientific Sessions. The biotech’s shares were at $1.86, up 67.6% from Monday’s close at $1.11, as of 07:02 a.m. EDT, according to MarketScreener. The stock trades on Nasdaq.
